{"version":"1.0","type":"link","title":"Phase I study of the safety and clinical activity of the interleukin-8 inhibitor AMY109 combined with atezolizumab in patients with advanced solid cancers.","author_name":"Yamamoto N 외","author_url":"https://prs-insight.online/author/Yamamoto%20N","provider_name":"PRSinsight","provider_url":"https://prs-insight.online","thumbnail_url":"https://prs-insight.online/og/paper/157104","thumbnail_width":1200,"thumbnail_height":630}